Immunological monitoring of the tumor immunoenvironment for clinical trials

Cancer Immunology, Immunotherapy

Volumn 61, Issue 2, 2012, Pages 239-247

  Malyguine, Anatoli M ^a   Strobl, Susan L ^a   Shurin, Michael R ^b  

^a SAIC FREDERICK INC   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

CITIM2011; Immunomonitoring; Leukocytes; Tumor immunoenvironment; Vaccine clinical trials

Indexed keywords

CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GRANZYME B; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA;

CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IMMUNOLOGICAL MONITORING; IMMUNOLOGICAL PARAMETERS; INTERNAL CONSISTENCY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RELIABILITY; REVIEW; STANDARDIZATION; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VALIDATION STUDY;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MONITORING, IMMUNOLOGIC; NEOPLASMS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84856740931     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1148-6     Document Type: Review

References (63)

1. J Lieberman 2003 The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal Nat Rev 3 361 370 10.1038/nri1083 1:CAS:528:DC%2BD3sXjvF2mt7o%3D (Pubitemid 37323196)
2. A Groth S Kloss EP von Strandmann U Koehl J Koch 2011 Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance J Innate Immun 3 344 354 21576922 10.1159/000327014 1:CAS:528:DC%2BC3MXnvF2jtr8%3D
3. A Schmittel U Keilholz E Thiel C Scheibenbogen 2000 Quantification of tumor-specific T lymphocytes with the ELISPOT assay J Immunother 23 289 295 10838657 10.1097/00002371-200005000-00001 1:STN:280:DC%2BD3czptlehtg%3D%3D (Pubitemid 30327363)
4. A Malyguine S Strobl L Zaritskaya M Baseler K Shafer-Weaver 2007 New approaches for monitoring CTL activity in clinical trials Adv Exp Med Biol 601 273 284 17713015 10.1007/978-0-387-72005-0-29
5. A Malyguine SL Strobl KA Shafer-Weaver T Ulderich A Troke M Baseler LW Kwak SS Neelapu 2004 A modified human ELISPOT assay to detect specific responses to primary tumor cell targets J Transl Med 2 9 15050026 10.1186/1479-5876-2-9 (Pubitemid 39130362)
6. FH Rininsland T Helms RJ Asaad BO Boehm M Tary-Lehmann 2000 Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity J Immunol Methods 240 143 155 10854609 10.1016/S0022-1759(00)00191-5 1:CAS:528:DC%2BD3cXjvFKgtL0%3D (Pubitemid 30347410)
7. K Shafer-Weaver T Sayers S Strobl E Derby T Ulderich M Baseler A Malyguine 2003 The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity J Transl Med 1 14 14697097 10.1186/1479-5876-1-14 (Pubitemid 39130334)
8. K Shafer-Weaver S Rosenberg S Strobl W Gregory Alvord M Baseler A Malyguine 2006 Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials J Immunother 29 328 335 16699376 10.1097/01.cji.0000203079. 35612.c8 1:CAS:528:DC%2BD28XksFKgtL4%3D (Pubitemid 44297301)
9. E Derby V Reddy W Kopp E Nelson M Baseler T Sayers A Malyguine 2001 Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity Immunol Lett 78 35 39 11470149 10.1016/S0165-2478(01) 00226-7 1:CAS:528:DC%2BD3MXltFyru74%3D (Pubitemid 32709904)
10. MW Burkett KA Shafer-Weaver S Strobl M Baseler A Malyguine 2005 A novel flow cytometric assay for evaluating cell-mediated cytotoxicity J Immunother 28 396 402 16000959 10.1097/01.cji.0000165357.11548.6d (Pubitemid 40962334)
11. L Zaritskaya KA Shafer-Weaver MK Gregory SL Strobl M Baseler A Malyguine 2009 Application of a flow cytometric cytotoxicity assay for monitoring cancer vaccine trials J Immunother 32 186 194 19238018 10.1097/CJI.0b013e318197b1b2 1:CAS:528:DC%2BD1MXit1Cju7c%3D
12. SA Rosenberg JC Yang NP Restifo 2004 Cancer immunotherapy: moving beyond current vaccines Nat Med 10 909 915 15340416 10.1038/nm1100 1:CAS:528: DC%2BD2cXntFSktL0%3D (Pubitemid 39273730)
13. CA Klebanoff N Acquavella Z Yu NP Restifo 2011 Therapeutic cancer vaccines: are we there yet? Immunol Rev 239 27 44 21198663 10.1111/j.1600-065X. 2010.00979.x 1:CAS:528:DC%2BC3MXhsVOgtrc%3D
14. MR Shurin M Gregory JC Morris AM Malyguine 2010 Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow? Expert Opin Biol Ther 10 1539 1553 20955111 10.1517/14712598.2010.526105 1:CAS:528: DC%2BC3cXhtlWmtLnM
15. SA Rosenberg RM Sherry KE Morton WJ Scharfman JC Yang SL Topalian RE Royal U Kammula NP Restifo MS Hughes D Schwartzentruber DM Berman SL Schwarz LT Ngo SA Mavroukakis DE White SM Steinberg 2005 Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma J Immunol 175 6169 6176 16237114 1:CAS:528:DC%2BD2MXhtFahu77P (Pubitemid 41508105)
16. H Okada P Kalinski R Ueda A Hoji G Kohanbash TE Donegan AH Mintz JA Engh DL Bartlett CK Brown H Zeh MP Holtzman TA Reinhart TL Whiteside LH Butterfield RL Hamilton DM Potter IF Pollack AM Salazar FS Lieberman 2011 Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma J Clin Oncol 29 330 336 21149657 10.1200/JCO.2010.30.7744 1:CAS:528:DC%2BC3MXit1yhurs%3D
17. A Ribas LH Camacho SM Lee EM Hersh CK Brown JM Richards MJ Rodriguez VG Prieto JA Glaspy DK Oseguera J Hernandez A Villanueva B Chmielowski P Mitsky N Bercovici E Wasserman D Landais MI Ross 2010 Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma J Transl Med 8 89 20875102 10.1186/1479-5876-8-89
18. DJ Schwartzentruber DH Lawson JM Richards RM Conry DM Miller J Treisman F Gailani L Riley K Conlon B Pockaj KL Kendra RL White R Gonzalez TM Kuzel B Curti PD Leming ED Whitman J Balkissoon DS Reintgen H Kaufman FM Marincola MJ Merino SA Rosenberg P Choyke D Vena P Hwu 2011 gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma N Engl J Med 364 2119 2127 21631324 10.1056/NEJMoa1012863 1:CAS:528:DC%2BC3MXnt1Cmt7Y%3D
19. TL Whiteside 2010 Immune responses to malignancies J Allergy Clin Immunol 125 S272 S283 20061007 10.1016/j.jaci.2009.09.045
20. LH Butterfield AK Palucka CM Britten MV Dhodapkar L Hakansson S Janetzki Y Kawakami TO Kleen PP Lee C Maccalli HT Maecker VC Maino M Maio A Malyguine G Masucci G Pawelec DM Potter L Rivoltini LG Salazar DJ Schendel CL Slingluff Jr W Song DF Stroncek H Tahara M Thurin G Trinchieri SH van Der Burg TL Whiteside JM Wigginton F Marincola S Khleif BA Fox ML Disis 2011 Recommendations from the iSBTc-SITC/FDA/NCI workshop on immunotherapy biomarkers Clin Cancer Res 17 3064 3076 21558394 10.1158/1078-0432.CCR-10-2234 1:CAS:528:DC%2BC3MXmtVGisLY%3D
21. JL Gulley PM Arlen RA Madan KY Tsang MP Pazdur L Skarupa JL Jones DJ Poole JP Higgins JW Hodge V Cereda M Vergati SM Steinberg S Halabi E Jones C Chen H Parnes JJ Wright WL Dahut J Schlom 2010 Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer Cancer Immunol Immunother 59 663 674 19890632 10.1007/s00262-009-0782-8 1:CAS:528:DC%2BC3cXis1yhtr8%3D
22. C Jochems J Schlom 2011 Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity Exp Biol Med (Maywood) 236 567 579 10.1258/ebm.2011.011007 1:CAS:528:DC%2BC3MXns1Smsbc%3D
23. JE Talmadge 2011 Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact Semin Cancer Biol 21 131 138 21145968 10.1016/j.semcancer.2010.12.002 1:CAS:528:DC%2BC3MXjs1Crtbo%3D
24. P Filipazzi R Valenti V Huber L Pilla P Canese M Iero C Castelli L Mariani G Parmiani L Rivoltini 2007 Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine J Clin Oncol 25 2546 2553 17577033 10.1200/JCO.2006.08.5829 1:CAS:528: DC%2BD2sXotV2mt7Y%3D (Pubitemid 47041228)
25. MP Gustafson Y Lin KC New PA Bulur BP O'Neill DA Gastineau AB Dietz 2010 Systemic immune suppression in glioblastoma: the interplay between CD14+ HLA-DRlo/neg monocytes, tumor factors, and dexamethasone Neuro-oncology 12 631 644 20179016 10.1093/neuonc/noq001 1:CAS:528:DC%2BC3cXps1WksLo%3D
26. S Vuk-Pavlovic PA Bulur Y Lin R Qin CL Szumlanski X Zhao AB Dietz 2010 Immunosuppressive CD14+ HLA-DRlow/- monocytes in prostate cancer Prostate 70 443 455 19902470 1:CAS:528:DC%2BC3cXktlSmsbg%3D
27. CM Diaz-Montero ML Salem MI Nishimura E Garrett-Mayer DJ Cole AJ Montero 2009 Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy Cancer Immunol Immunother 58 49 59 18446337 10.1007/s00262-008- 0523-4 1:CAS:528:DC%2BD1cXht1yqs7bN
28. P Serafini S Mgebroff K Noonan I Borrello 2008 Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells Cancer Res 68 5439 5449 18593947 10.1158/0008-5472.CAN-07-6621 1:CAS:528:DC%2BD1cXnvFyjur4%3D
29. MK Srivastava P Sinha VK Clements P Rodriguez S Ostrand-Rosenberg 2010 Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine Cancer Res 70 68 77 20028852 10.1158/0008-5472.CAN-09-2587 1:CAS:528:DC%2BC3cXltVaj
30. S Solito E Falisi CM Diaz-Montero A Doni L Pinton A Rosato S Francescato G Basso P Zanovello G Onicescu E Garrett-Mayer AJ Montero V Bronte S Mandruzzato 2010 A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells Blood 118 2254 2265 10.1182/blood-2010-12-325753
31. MR Shurin GV Shurin A Lokshin ZR Yurkovetsky DW Gutkin G Chatta H Zhong B Han RL Ferris 2006 Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 25 333 356 17029028 10.1007/s10555-006-9010-6 1:CAS:528:DC%2BD28Xht1yktb3L (Pubitemid 44922354)
32. SA Quezada KS Peggs TR Simpson JP Allison 2011 Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication Immunol Rev 241 104 118 21488893 10.1111/j.1600-065X.2011.01007.x 1:CAS:528:DC%2BC3MXlsFOjs7Y%3D
33. F Pages J Galon MC Dieu-Nosjean E Tartour C Sautes-Fridman WH Fridman 2009 Immune infiltration in human tumors: a prognostic factor that should not be ignored Oncogene 29 1093 1102 19946335 10.1038/onc.2009.416
34. SJ Piersma ES Jordanova MI van Poelgeest KM Kwappenberg JM van der Hulst JW Drijfhout CJ Melief GG Kenter GJ Fleuren R Offringa SH van der Burg 2007 High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer Cancer Res 67 354 361 17210718 10.1158/0008-5472.CAN-06-3388 1:CAS:528:DC%2BD2sXisFSqsg%3D%3D (Pubitemid 46142795)
35. O Kawai G Ishii K Kubota Y Murata Y Naito T Mizuno K Aokage N Saijo Y Nishiwaki A Gemma S Kudoh A Ochiai 2008 Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer Cancer 113 1387 1395 18671239 10.1002/cncr.23712 1:CAS:528:DC%2BD1cXhtFyls7rL
36. F Pages A Kirilovsky B Mlecnik M Asslaber M Tosolini G Bindea C Lagorce P Wind F Marliot P Bruneval K Zatloukal Z Trajanoski A Berger WH Fridman J Galon 2009 In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer J Clin Oncol 27 5944 5951 19858404 10.1200/JCO.2008.19.6147 1:CAS:528:DC%2BC3cXhtVWisL8%3D
37. GF Murphy A Radu M Kaminer D Berd 1993 Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: relevance to immunologic regression and immunotherapy J Investig Dermatol 100 335S 341S 8440919 10.1038/jid.1993.59 1:STN:280:DyaK3s7nvFOltw%3D%3D (Pubitemid 23083194)
38. C Jandus G Bioley DE Speiser P Romero 2008 Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood Cancer Immunol Immunother 57 1795 1805 18414854 10.1007/s00262-008-0507-4 1:CAS:528:DC%2BD1cXhtFCgu7jK
39. TJ Curiel P Cheng P Mottram X Alvarez L Moons M Evdemon-Hogan S Wei L Zou I Kryczek G Hoyle A Lackner P Carmeliet W Zou 2004 Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer Cancer Res 64 5535 5538 15313886 10.1158/0008-5472.CAN-04-1272 1:CAS:528:DC%2BD2cXmslaltb8%3D (Pubitemid 39095544)
40. FA Sinicrope RL Rego SM Ansell KL Knutson NR Foster DJ Sargent 2009 Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma Gastroenterology 137 1270 1279 19577568 10.1053/j.gastro.2009.06.053 1:CAS:528:DC%2BD1MXht12gtr%2FP
41. P Salama M Phillips F Grieu M Morris N Zeps D Joseph C Platell B Iacopetta 2009 Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer J Clin Oncol 27 186 192 19064967 10.1200/JCO.2008.18.7229
42. DT Le BH Ladle T Lee V Weiss X Yao A Leubner TD Armstrong EM Jaffee 2011 CD8 Foxp3 tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response Int J Cancer 129 636 647 20857491 10.1002/ijc.25693 1:CAS:528:DC%2BC3MXmsFGisbo%3D
43. Chen KJ, Zhou L, Xie HY, Ahmed TE, Feng XW, Zheng SS (2011) Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection. Med Oncol (in press)
44. F Liu R Lang J Zhao X Zhang GA Pringle Y Fan D Yin F Gu Z Yao L Fu 2011 CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes Breast Cancer Res Treat 130 645 655 21717105 10.1007/s10549-011-1647-3 1:CAS:528:DC%2BC3MXht1yktL3J
45. RD Leek CE Lewis R Whitehouse M Greenall J Clarke AL Harris 1996 Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma Cancer Res 56 4625 4629 8840975 1:CAS:528: DyaK28XmsV2isbk%3D (Pubitemid 26338061)
46. L Bingle NJ Brown CE Lewis 2002 The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies J Pathol 196 254 265 11857487 10.1002/path.1027 1:STN:280:DC%2BD387it1eksQ%3D%3D (Pubitemid 34189413)
47. S Shimura G Yang S Ebara TM Wheeler A Frolov TC Thompson 2000 Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression Cancer Res 60 5857 5861 11059783 1:CAS:528:DC%2BD3cXnvVSnt7Y%3D
48. S Nagaraj DI Gabrilovich 2010 Myeloid-derived suppressor cells in human cancer Cancer J 16 348 353 20693846 10.1097/PPO.0b013e3181eb3358 1:CAS:528:DC%2BC3cXhtFGnurjM
49. T Condamine DI Gabrilovich 2011 Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function Trends Immunol 32 19 25 21067974 10.1016/j.it.2010.10.002 1:CAS:528:DC%2BC3MXkt1CmsA%3D%3D
50. P Goedegebuure JB Mitchem MR Porembka MC Tan BA Belt A Wang-Gillam WE Gillanders WG Hawkins DC Linehan 2011 Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer Curr Cancer Drug Targets 11 734 751 21599634 10.2174/156800911796191024 1:CAS:528:DC%2BC3MXptlegu74%3D
51. H Naiditch MR Shurin GV Shurin 2011 Targeting myeloid regulatory cells in cancer by chemotherapeutic agents Immunol Res 50 276 285 21717082 10.1007/s12026-011-8213-2 1:CAS:528:DC%2BC3MXptFaisrs%3D
52. D Nagorsen S Voigt E Berg H Stein E Thiel C Loddenkemper 2007 Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival J Transl Med 5 62 18047662 10.1186/1479-5876-5-62 (Pubitemid 351167703)
53. YW Li SJ Qiu J Fan J Zhou Q Gao YS Xiao YF Xu 2010 Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection J Hepatol 54 497 505 21112656 10.1016/j.jhep.2010.07.044
54. P Sharma Y Shen S Wen S Yamada AA Jungbluth S Gnjatic DF Bajorin VE Reuter H Herr LJ Old E Sato 2007 CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma Proc Natl Acad Sci USA 104 3967 3972 17360461 10.1073/pnas.0611618104 1:CAS:528: DC%2BD2sXjt1ymu7g%3D (Pubitemid 47181562)
55. N Leffers MJ Gooden RA de Jong BN Hoogeboom KA ten Hoor H Hollema HM Boezen AG van der Zee T Daemen HW Nijman 2009 Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer Cancer Immunol Immunother 58 449 459 18791714 10.1007/s00262-008-0583-5
56. R Uppaluri GP Dunn JS Lewis Jr 2008 Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers Cancer Immun 8 16 19053167
57. H Ohtani 2007 Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer Cancer Immun 7 4 17311363
58. SM Mahmoud EC Paish DG Powe RD Macmillan MJ Grainge AH Lee IO Ellis AR Green 2011 Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer J Clin Oncol 29 1949 1955 21483002 10.1200/JCO.2010.30.5037
59. A Ashida N Boku K Aoyagi H Sato Y Tsubosa K Minashi M Muto A Ohtsu A Ochiai T Yoshida S Yoshida H Sasaki 2006 Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications Int J Oncol 28 1345 1352 16685435 1:CAS:528: DC%2BD28XlvVOiurY%3D
60. P Lu XQ Zhu ZL Xu Q Zhou J Zhang F Wu 2009 Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer Surgery 145 286 293 19231581 10.1016/j.surg.2008.10.010
61. H Hornychova B Melichar M Tomsova J Mergancova H Urminska A Ryska 2008 Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma Cancer Invest 26 1024 1031 19093260 10.1080/07357900802098165 1:CAS:528:DC%2BD1cXhsFagtLvP
62. Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, von Knebel Doeberitz M, Folprecht G, Luber B, Feyen N, Martens UM, Beckhove P, Gnjatic S, Schirmacher P, Herpel E, Weitz J, Grabe N, Jaeger D (2011) Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 71:5670-5677
63. A Cipponi G Wieers N van Baren PG Coulie 2011 Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol Immunother 60 1153 1160 21553145 10.1007/s00262-011-1026-2